Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies

Nature Structural and Molecular Biology

Volumn 17, Issue 12, 2010, Pages 1486-1491

  Frey, Gary ^a,b   Chen, Jia ^a,b   Rits Volloch, Sophia ^a,b   Freeman, Michael M ^a,b   Zolla Pazner, Susan ^c,d   Chen, Bing ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY Z13E1; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; MEMBRANE FUSION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRUS ENTRY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649861760     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1950     Document Type: Article

References (60)

1. Harrison, S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690-698 (2008).
2. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
3. Allan, J.S. et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228, 1091-1094 (1985).
4. Veronese, F.D. et al. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229, 1402-1405 (1985).
5. Harrison, S.C. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res. 64, 231-261 (2005).
6. Chan, D.C. & Kim, P.S. HIV entry and its inhibition. Cell 93, 681-684 (1998).
7. Kilby, J.M. & Eron, J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348, 2228-2238 (2003).
8. Wild, C., Oas, T., McDanal, C., Bolognesi, D. & Matthews, T. A synthetic peptide inhibitor of human immunodefciency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89, 10537-10541 (1992).
9. Frey, G. et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 105, 3739-3744 (2008).
10. Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
11. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. & Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997).
12. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003).
13. Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
14. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
15. Stamatatos, L., Morris, L., Burton, D.R. & Mascola, J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866-870 (2009).
16. Wu, X. et al. Rational design of envelope identifes broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
17. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
18. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
19. Trkola, A. et al. Human monoclonal antibody 2G12 defnes a distinctive neutralization epitope on the gp120 glycoprotein of human immunodefciency virus type 1. J. Virol. 70, 1100-1108 (1996).
20. Burton, D.R. et al. Effcient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
21. Hioe, C.E. et al. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS ONE 5, e10254 (2010).
22. Zolla-Pazner, S. & Cardozo, T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10, 527-535 (2010).
23. Stiegler, G. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodefciency virus type 1. AIDS Res. Hum. Retroviruses 17, 1757-1765 (2001).
24. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodefciency virus type 1. J. Virol. 67, 6642-6647 (1993).
25. Zwick, M.B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodefciency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
26. Alam, S.M. et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 106, 20234-20239 (2009).
27. Xu, J.Y., Gorny, M.K., Palker, T., Karwowska, S. & Zolla-Pazner, S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodefciency virus type 1, using ten human monoclonal antibodies. J. Virol. 65, 4832-4838 (1991).
28. Hioe, C.E. et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9, 1281-1290 (1997).
29. Holl, V. et al. Nonneutralizing antibodies are able to inhibit human immunodefciency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80, 6177-6181 (2006).
30. Gorny, M.K., Gianakakos, V., Sharpe, S. & Zolla-Pazner, S. Generation of human monoclonal antibodies to human immunodefciency virus. Proc. Natl. Acad. Sci. USA 86, 1624-1628 (1989).
31. Gorny, M.K., VanCott, T.C., Williams, C., Revesz, K. & Zolla-Pazner, S. Effects of oligomerization on the epitopes of the human immunodefciency virus type 1 envelope glycoproteins. Virology 267, 220-228 (2000).
32. Pinter, A. et al. Oligomeric structure of gp41, the transmembrane protein of human immunodefciency virus type 1. J. Virol. 63, 2674-2679 (1989).
33. Gorny, M.K. & Zolla-Pazner, S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodefciency virus type 1 gp41. J. Virol. 74, 6186-6192 (2000).
34. Yuan, W. et al. Oligomer-specifc conformations of the human immunodefciency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. AIDS Res. Hum. Retroviruses 25, 319-328 (2009).
35. Nelson, J.D. et al. An affnity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodefciency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81, 4033-4043 (2007).
36. Harbury, P.B., Kim, P.S. & Alber, T. Crystal structure of an isoleucine-zipper trimer. Nature 371, 80-83 (1994).
37. Aoki, S.T. et al. Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science 324, 1444-1447 (2009).
38. Caffrey, M. et al. Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41. EMBO J. 17, 4572-4584 (1998).
39. Yang, Z.N. et al. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J. Struct. Biol. 126, 131-144 (1999).
40. Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodefciency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
41. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled effcacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
42. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
43. Nyambi, P.N. et al. Conserved and exposed epitopes on intact, native, primary human immunodefciency virus type 1 virions of group M. J. Virol. 74, 7096-7107 (2000).
44. Schülke, N. et al. Oligomeric and conformational properties of a proteolytically mature, disulfde-stabilized human immunodefciency virus type 1 gp140 envelope glycoprotein. J. Virol. 76, 7760-7776 (2002).
45. Muñoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E. & Blumenthal, R. Dilation of the human immunodefciency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315-323 (1998).
46. Steger, H.K. & Root, M.J. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem. 281, 25813-25821 (2006).
47. Moore, P.L. et al. Nature of nonfunctional envelope proteins on the surface of human immunodefciency virus type 1. J. Virol. 80, 2515-2528 (2006).
48. Alsmadi, O. & Tilley, S.A. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodefciency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specifcities. J. Virol. 72, 286-293 (1998).
49. Tyler, D.S. et al. Identifcation of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145, 3276-3282 (1990).
50. Forthal, D.N., Landucci, G., Gorny, M.K., Zolla-Pazner, S. & Robinson, W.E. Jr. Functional activities of 20 human immunodefciency virus type 1 (HIV-1)-specifc human monoclonal antibodies. AIDS Res. Hum. Retroviruses 11, 1095-1099 (1995).
51. Pietzsch, J. et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J. Virol. 84, 5032-5042 (2010).
52. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25 (1997).
53. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
54. Strong, M. et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103, 8060-8065 (2006).
55. Jones, T.A. & Kjeldgaard, M. Electron-density map interpretation. Methods Enzymol. 277, 173-208 (1997).
56. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
57. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
58. Murshudov, G.N. Refnement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
59. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291 (1993).
60. DeLano, W.L. The PyMOL User's Manual (DeLano Scientifc, San Carlos, California, USA, 2002).